Synthesis and structure-activity relationships of new β-adrenoreceptor antagonists. Evidence for the electrostatic requirements for β-adrenoreceptor antagonists

[1]  V. Kettmann,et al.  Structure of ethyl 2‐[(2‐hydroxy‐3‐isopropylamino)propoxy]carbanilate hydrochloride , 1989 .

[2]  P. Carrupt,et al.  Modeling of beta-adrenoceptors based on molecular electrostatic potential studies of agonists and antagonists. , 1988, Journal of medicinal chemistry.

[3]  R. Boča.  Inclusion of relativistic effects into ZDO methods. I. A quasi‐relativistic CNDO/1 , 1987 .

[4]  J. Binet,et al.  Synthesis of a series of compounds related to betaxolol, a new beta 1-adrenoceptor antagonist with a pharmacological and pharmacokinetic profile optimized for the treatment of chronic cardiovascular diseases. , 1987, Journal of medicinal chemistry.

[5]  Adriaan P. IJzerman,et al.  Factors controlling β1-adrenoceptor affinity and selectivity , 1985 .

[6]  P. Maroko,et al.  Comparative Effects of Dobutamine and Corwin, a β1‐Adrenergic Partial Agonist, in Experimental Left Ventricular Failure , 1985, Journal of cardiovascular pharmacology.

[7]  M. Remko,et al.  Ab initio investigations on the local anesthetics procaine, lidocaine and heptacaine , 1983 .

[8]  W. Eckelman,et al.  Cardioselectivity of beta-adrenoceptor blocking agents. 2. Role of the amino group substituent. , 1983, Journal of medicinal chemistry.

[9]  Peter A. Kollman,et al.  AMBER: Assisted model building with energy refinement. A general program for modeling molecules and their interactions , 1981 .

[10]  H. Tucker.  Beta-adrenergic blocking agents. 20. (3-Hydroxyprop-1-enyl)-substituted 1-(aryloxy)-3-(alkylamino)propan-2-ols. , 1980, Journal of medicinal chemistry.

[11]  P. D. de Feyter,et al.  Clinical, Electrocardiographic, and Hemodynamic Effects of ICI 89,406, a New Cardioselective Beta‐Adrenoceptor Antagonist with Intrinsic Sympathomimetic Activity, in Patients with Angina Pectoris , 1980, Journal of cardiovascular pharmacology.

[12]  W. Frishman.  Clinical pharmacology of the new beta-adrenergic blocking drugs. Part 13. The beta-adrenoceptor blocking drugs: a perspective. , 1980, American heart journal.

[13]  M Karplus,et al.  Side-chain torsional potentials: effect of dipeptide, protein, and solvent environment. , 1979, Biochemistry.

[14]  F. Weinhold,et al.  Quantum-mechanical studies on the origin of barriers to internal rotation about single bonds , 1979 .

[15]  D. Mackay.  How should values of pA2 and affinity constants for pharmacological competitive antagonists be estimated? , 1978, The Journal of pharmacy and pharmacology.

[16]  G. Shtacher,et al.  Cardioselectivity as a function of molecular structure in beta-adrenoceptor blocking agents of the 1-(para-substituted aryloxy)-3-(isopropylamino)propan-2-ol type. , 1978, Journal of medicinal chemistry.

[17]  D. Azarnoff,et al.  Pamatolol: Phase I evaluation of the pharmacodynamics of a cardioselective beta adrenoceptor blocking drug , 1978, Clinical pharmacology and therapeutics.

[18]  Norman L. Allinger,et al.  Conformational analysis. 130. MM2. A hydrocarbon force field utilizing V1 and V2 torsional terms , 1977 .

[19]  M. Burke-Laing,et al.  Structures of nitrogen-containing aromatic compounds. III. Benzalazine, redetermination and refinement , 1976 .

[20]  Claude Giessner-Prettre,et al.  On the molecular electrostatic potentials obtained from CNDO wave functions , 1975 .

[21]  A. Holmes,et al.  Cardioselective beta-adrenergic blocking agents. 1. 1-((3,4-Dimethoxyphenethyl)amino)-3-aryloxy-2-propanols. , 1975, Journal of medicinal chemistry.

[22]  Charles Tanford,et al.  Theory of micelle formation in aqueous solutions , 1974 .

[23]  D. Maxwell,et al.  β‐Adrenoceptor blocking properties and cardioselectivity of M & B 17,803A , 1973, British journal of pharmacology.

[24]  C. Giessner-Prettre,et al.  Molecular electrostatic potentials: Comparison of ab initio and CNDO results , 1972 .

[25]  L. H. Smith,et al.  Beta-adrenergic blocking agents. 10. (3-amino-2-hydroxypropoxy)anilides. , 1971, Journal of medicinal chemistry.

[26]  L. H. Amundsen,et al.  Rearrangements of o-Aminophenyl Esters , 1966 .

[27]  H. Jaffe,et al.  Theory and Applications of Ultraviolet Spectroscopy , 1962 .

[28]  K. Takagi,et al.  Chemicopharmacological Studies on Antispasmodic Action. XV. Non-specific Antispasmodic Action on Tracheal Muscle. , 1958 .

[29]  C. E. Slimowicz,et al.  Preparation and Properties of Certain Alkyl Azamalonates , 1949 .

[30]  F. Brown,et al.  The Friedel—Crafts Reaction with o-Nitrophenol and Acyl Halides1 , 1946 .

[31]  A. Martinelli,et al.  MO STUDIES ON THE MECHANISM OF DRUG RECEPTOR INTERACTION .4. INTERACTING CONFORMATIONS OF BETA-ADRENERGIC DRUGS , 1983 .

[32]  A. Martinelli,et al.  Ab initio study of the internal rotation and of the electrostatic molecular potential of a model compound of tazolol and comparison with similar compounds , 1980 .